Relay Therapeutics (RLAY) Scheduled to Post Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Relay Therapeutics to post earnings of ($0.77) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the firm earned ($0.81) EPS. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Price Performance

RLAY stock opened at $5.72 on Thursday. The company has a 50 day simple moving average of $6.93 and a 200 day simple moving average of $7.03. The stock has a market cap of $765.85 million, a price-to-earnings ratio of -2.27 and a beta of 1.64. Relay Therapeutics has a 1 year low of $5.70 and a 1 year high of $12.14.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RLAY. Bank of America boosted their target price on shares of Relay Therapeutics from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. JPMorgan Chase & Co. reduced their target price on shares of Relay Therapeutics from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Tuesday, September 10th. Stifel Nicolaus reissued a “buy” rating and set a $28.00 target price on shares of Relay Therapeutics in a report on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Relay Therapeutics in a report on Monday, October 14th. Finally, Barclays boosted their target price on shares of Relay Therapeutics from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.11.

Insider Activity

In other news, CFO Thomas Catinazzo sold 6,802 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $6.06, for a total value of $41,220.12. Following the sale, the chief financial officer now directly owns 306,391 shares of the company’s stock, valued at approximately $1,856,729.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.32% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.